QuartrQuartr

KEQU: FY2026 revenue and EBITDA surged, driven by platform integration and global expansion

Less than 1 min read

Revenue and EBITDA saw significant growth over five years, with FY2026 revenue at $282M and EBITDA at $22.4M. Strategic initiatives included the formation of the Lab Products Group, international expansion, and enhanced governance. Key risks and forward-looking statements were discussed.

Original document: Kewaunee Scientific Corporation [KEQU] Slides Release — Aug. 26 2026

Disclaimer